Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
The downturn comes as the head of drugmaker Moderna (MRNA) told the Financial Times that COVID-19 vaccines are unlikely to be as effective against the Omicron variant as they have been against the Delta strain.
“I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like, ‘This is not going to be good’.”